# US 7,612,111 B2 · Esterified fatty acid composition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,612,111 B2 - Document ID: US7612111B2 - Status: Granted - Kind: B2 - Application number: 10/805,386 - Filed: 2004-03-22 - Published: 2005-09-22 - Granted: 2009-11-03 - Earliest claimed: 2003-03-20 - Assignees: Imagenetix, Inc. - Inventors: William P. Spencer; Patrick S. Millsap - Web page: https://patentgrep.com/patent/US7612111B2 ## CPC - A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms - A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids - A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 31/225: Polycarboxylic acids - A61K 31/231: having one or two double bonds - A61K 31/355: Tocopherols, e.g. vitamin E - A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin - A61K 36/63: Oleaceae (Olive family), e.g. jasmine, lilac or ash tree - A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 17/06: Antipsoriatics - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents - A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions of the present invention have the advantage of increased stability, a reduction of arachidonic acid in cells, a reduction in eicosanoid production and enhanced cell regulation and communication. Also disclosed are methods for using the compositions for treatment and prevention. ## Claims ### Claim 1 A method of treating periodontal disease comprising administering an effective amount of a composition comprising a cetylated fatty acid and a carrier or an excipient to a subject in need of such treatment, wherein the cetylated fatty acid is selected from the group consisting of cetylated decanoic acid, cetylated lauric acid, cetylated myristic acid, cetylated palmitoleic acid, cetylated oleic acid, and cetylated stearic acid, and wherein the carrier or excipients is selected from the group consisting of lecithin, olive oil, and tocophenol. ### Claim 2 (depends on 1) The method of claim 1, wherein the subject is a mammal. ### Claim 3 (depends on 2) The method of claim 2, wherein the mammal is human. ### Claim 4 (depends on 2) The method of claim 2, wherein the mammal is canine or feline. ### Claim 5 (depends on 1) The method of claim 1, wherein the composition is administered via topical application. ### Claim 6 (depends on 5) The method of claim 5, wherein the amount of the composition administered is about 1 to 15 mg/kg of body weight of said subject per day. ### Claim 7 (depends on 5) The method of claim 5, wherein the amount of the composition administered is about 3 to 10 mg/kg of body weight of said subject per day. ### Claim 8 (depends on 5) The method of claim 5, wherein the amount of the composition administered is about 5 to 8 mg/kg of body weight of said subject per day. ### Claim 9 (depends on 1) The method of claim 1, wherein the composition is administered orally. ### Claim 10 (depends on 9) The method of claim 9, wherein the amount of the composition administered is about 5 to 32 mg/kg of body weight of said subject per day. ### Claim 11 (depends on 9) The method of claim 9, wherein the amount of the composition administered is about 10 to 30 mg/kg of body weight of said subject per day. ### Claim 12 (depends on 9) The method of claim 9, wherein the amount of the composition administered is about 15 to 25 mg/kg of body weight of said subject per day. ### Claim 13 (depends on 9) The method of claim 9, wherein the composition is administered via a soft gel. ### Claim 14 (depends on 1) The method of claim 1, wherein the composition is administered once a day. ### Claim 15 (depends on 1) The method of claim 1, wherein the composition is administered twice a day. ### Claim 16 (depends on 1) The method of claim 1, wherein the composition is administered to a subject in combination with another compound or therapy effective to treat periodontal disease. ### Claim 17 (depends on 1) The method of claim 1, wherein the carrier or excipient is olive oil. ### Claim 18 (depends on 1) The method of claim 1, wherein the cetylated fatty acid is cetylated myristic acid. ### Claim 19 (depends on 1) The method of claim 1, wherein the composition comprises from about 1% to about 10% of a lecithin fatty acid. ### Claim 20 (depends on 1) The method of claim 1, wherein the composition comprises from about 15% to about 25% olive oil. ### Claim 21 (depends on 1) The method of claim 1, wherein the composition comprises from about 70% to about 80% of an esterified fatty acid. ### Claim 22 (depends on 1) The method of claim 1, wherein the composition comprises about 1% to about 5% of a tocophenol. ### Claim 23 (depends on 1) The method of claim 1, wherein the composition comprises from about 1% to about 10% of a lecithin fatty acid, from about 15% to about 25% olive oil fatty acid, from about 70% to about 80% of a cetylated fatty acid, and from about 1% to about 5% of a tocophenol. ### Claim 24 (depends on 1) The method of claim 1, wherein the composition comprises about 74% cetylated fatty acid. ### Claim 25 (depends on 1) The method of claim 1, wherein the composition comprises about 5% lecithin. ### Claim 26 (depends on 1) The method of claim 1, wherein the composition comprises about 20% olive oil. ### Claim 27 (depends on 1) The method of claim 1, wherein the composition comprises about 1% tocophenols. ### Claim 28 (depends on 1) The method of claim 1, wherein the composition comprises about 5% lecithin, about 20% olive oil, 74% cetylated fatty acid, and about 1% tocophenols.